Gilead Sciences (GILD) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed Gilead Sciences (GILD) over the past year, gaining 34.3% versus a gain of 24.4%. Over five years, GILD leads with a +117.5% price change compared with -60.6% for OGN. Gilead Sciences is the larger company by market cap ($182.40 billion vs $3.61 billion), about 50.5 times the size.
On valuation, Organon trades at a lower forward P/E (3.8x vs 14.9x for Gilead Sciences). Gilead Sciences offers the higher dividend yield (2.19% vs 0.58%). Gilead Sciences converts more of its revenue into profit, with a net margin of 28.9% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GILD | OGN |
|---|---|---|
| Share price | $147.10 | $13.75 |
| Market cap | $182.40B | $3.61B |
| 1-day change | +0.17% | -0.29% |
| YTD return | +19.85% | +91.77% |
| 1-year return | +24.40% | +34.28% |
| 5-year return | +117.51% | -60.59% |
| P/E ratio (TTM) | — | 17.63 |
| Forward P/E | 14.87 | 3.80 |
| EPS (TTM) | $-2.65 | $0.78 |
| Dividend yield | 2.19% | 0.58% |
| Annual dividend | $3.22 | $0.08 |
| Revenue (latest FY) | $29.44B | $6.22B |
| Revenue growth (YoY) | +2.40% | -2.92% |
| Net income (latest FY) | $8.51B | $187.00M |
| Gross margin | 78.83% | 53.30% |
| Operating margin | 34.04% | — |
| Net margin | 28.90% | 3.01% |
| 52-week high | $157.29 | $13.80 |
| 52-week low | $114.02 | $5.69 |
| Distance from 52-week high | -6.48% | -0.36% |
| Analyst consensus | buy | none |
| Avg. price target upside | +8.27% | -18.18% |
| Average volume | 5.99M | 2.66M |
| Shares outstanding | 1.24B | 262.61M |
| Employees | 17,000 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Gilead Sciences is about 50.5 times larger than Organon by market value ($182.40B vs $3.61B).
- Gilead Sciences offers a meaningfully higher dividend yield (2.19% vs 0.58%).
- Gilead Sciences is more profitable, keeping 28.9 cents of every revenue dollar as net income versus 3.0 cents for Organon.
- Gilead Sciences grew revenue faster in its latest fiscal year (+2.40% vs -2.92%).
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17,000 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
GILD vs OGN FAQ
Which is bigger, Gilead Sciences or Organon?
Gilead Sciences (GILD) is larger, with a market capitalization of $182.40B compared with $3.61B for Organon (OGN).
Which stock has performed better over the past year, GILD or OGN?
OGN returned +34.28% over the past 12 months, compared with +24.40% for GILD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gilead Sciences or Organon?
Gilead Sciences has the higher yield at 2.19%, compared with 0.58% for Organon.
Are Gilead Sciences and Organon in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Gilead Sciences and Biotechnology: Pharmaceutical Preparations for Organon.